arrow
K

Kenji Ashida

division of endocrinology and metabolism
H指数:20
被引数:1,181

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes

2型糖尿病患者在SGLT2抑制剂治疗后,低基线HbA1c和降低的eGFR与相对不利的身体重组相关

2026-08-280
OAAI
Sodium-glucose cotransporter 2 inhibitors—but not insulin—enhance renal branched-chain amino acid catabolism

Sodium-glucose cotransporter 2抑制剂——而非胰岛素——可增强肾脏支链氨基酸分解代谢

2025-11-070
OAAI
Body Muscle-to-Fat Ratio (BMFR) as a Promising Anthropometric Index for Use in the Evaluation of Insulin Resistance and Metabolic Disease Risk: a Narrative Review

肌肉-脂肪比(BMFR)作为评估胰岛素抵抗和代谢疾病风险的潜在人体测量指标:一项叙事性综述

2025-10-290
OA
Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells

Nomura, S.; Wang, L.; Hasuzawa, N.; Nagayama, A.; Moriyama, S.; Ashida, K.; Moriyama, Y.; Nomura, M.; Yamamoto, K. Imeglimin通过抑制肝星状细胞中囊泡ATP释放来减轻肝纤维化。FEBS Lett. 2025. advance online publication. [Google Scholar] [CrossRef]

2025-09-011
OAAI
High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan
2019-03-2780
OAAI